

# Robin M Joyce

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5865985/publications.pdf>

Version: 2024-02-01

75  
papers

1,306  
citations

394421

19  
h-index

377865

34  
g-index

75  
all docs

75  
docs citations

75  
times ranked

2204  
citing authors

#	ARTICLE	IF	CITATIONS
1	Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions. <i>Science Translational Medicine</i> , 2016, 8, 368ra171.	12.4	140
2	MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia. <i>Blood</i> , 2017, 129, 1791-1801.	1.4	130
3	PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation. <i>Blood</i> , 2019, 134, 22-29.	1.4	129
4	Odronextamab (REGN1979), a Human CD20 x CD3 Bispecific Antibody, Induces Durable, Complete Responses in Patients with Highly Refractory B-Cell Non-Hodgkin Lymphoma, Including Patients Refractory to CAR T Therapy. <i>Blood</i> , 2020, 136, 42-43.	1.4	87
5	Protective antibody responses to pneumococcal conjugate vaccine after autologous hematopoietic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 213-222.	2.0	60
6	A phase 2 study of Rituximab+Bendamustine and Rituximab+Cytarabine for transplant-eligible patients with mantle cell lymphoma. <i>British Journal of Haematology</i> , 2016, 173, 89-95.	2.5	51
7	Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL). <i>Blood</i> , 2019, 134, 762-762.	1.4	50
8	PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation. <i>Blood Advances</i> , 2020, 4, 122-126.	5.2	46
9	Heparin induced thrombocytopenia antibodies in Covid-19. <i>American Journal of Hematology</i> , 2020, 95, E295.	4.1	45
10	Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. <i>Leukemia</i> , 2021, 35, 2672-2683.	7.2	45
11	Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma. <i>Blood</i> , 2019, 134, 606-613.	1.4	41
12	Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma. <i>Blood Advances</i> , 2020, 4, 858-867.	5.2	40
13	Transduction of Malignant Plasma Cells with Three Costimulatory Molecules (TRICOM) Elicits Myeloma-Specific Immune Response in Vitro – a Promising Strategy for Immunotherapy. <i>Blood</i> , 2012, 120, 1908-1908.	1.4	35
14	Lenalidomide, Bortezomib, and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma: Encouraging Efficacy in High Risk Groups with Updated Results of a Phase I/II Study. <i>Blood</i> , 2008, 112, 92-92.	1.4	34
15	Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma. <i>Blood</i> , 2015, 126, 354-362.	1.4	31
16	Phase 1 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease. <i>Blood</i> , 2018, 131, 2836-2845.	1.4	30
17	Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma. <i>Blood Advances</i> , 2021, 5, 1648-1659.	5.2	28
18	Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance-conferring FLT3/tyrosine kinase domain/F691 mutation. <i>Cancer</i> , 2018, 124, 306-314.	4.1	23

#	ARTICLE	IF	CITATIONS
19	Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia. <i>Blood Advances</i> , 2019, 3, 1167-1174.	5.2	23
20	Dose-adjusted enoxaparin thromboprophylaxis in hospitalized cancer patients: a randomized, double-blinded multicenter phase 2 trial. <i>Blood Advances</i> , 2020, 4, 2254-2260.	5.2	22
21	Vaccination with DC/Multiple Myeloma Fusions in Conjunction with Stem Cell Transplantation.. <i>Blood</i> , 2007, 110, 578-578.	1.4	19
22	Reduced-Intensity Conditioning Regimens, Prior Chronic Lymphocytic Leukemia, and Graft-Versus-Host Disease Are Associated with Higher Rates of Skin Cancer after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Journal of Investigative Dermatology</i> , 2019, 139, 591-599.	0.7	17
23	Phase 1 Study of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients with CD20+ B-Cell Malignancies Previously Treated with CD20-Directed Antibody Therapy. <i>Blood</i> , 2016, 128, 621-621.	1.4	16
24	Ofatumumab As Initial Therapy For Indolent B Cell Lymphomas: A Phase II Trial. <i>Blood</i> , 2013, 122, 3062-3062.	1.4	14
25	Psoriasisiform eruptions secondary to phosphoinositide 3-kinase inhibition. <i>JAAD Case Reports</i> , 2019, 5, 401-405.	0.8	10
26	Lenalidomide, Bortezomib, and Dexamethasone (Rev/Vel/Dex) as Front-Line Therapy for Patients with Multiple Myeloma (MM): Preliminary Results of a Phase 1/2 Study.. <i>Blood</i> , 2007, 110, 187-187.	1.4	10
27	Blockade of PD-1 in Combination with Dendritic Cell/Myeloma Fusion Cell Vaccination Following Autologous Stem Cell Transplantation Is Well Tolerated, Induces Anti-Tumor Immunity and May Lead to Eradication of Measurable Disease. <i>Blood</i> , 2015, 126, 4218-4218.	1.4	10
28	Open notes sounds great, but will a provider's documentation change? An exploratory study of the effect of open notes on oncology documentation. <i>JAMIA Open</i> , 2021, 4, ooab051.	2.0	8
29	Clinical Trial Evaluating DC/AML Fusion Cell Vaccination In AML Patients. <i>Blood</i> , 2013, 122, 3928-3928.	1.4	7
30	Immune Reconstitution following High-Dose Chemotherapy and Autologous Stem Cell Transplantation with or without Pembrolizumab Maintenance Therapy in Patients with Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 32.e1-32.e10.	1.2	7
31	Blockade of PD-1 in Combination with Dendritic Cell/Myeloma Fusion Cell Vaccination Following Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, S109.	2.0	6
32	Primary Cardiac Burkitt Lymphoma Presenting with Abdominal Pain. <i>Case Reports in Hematology</i> , 2014, 2014, 1-4.	0.4	6
33	Bendamustine Is Safe and Effective in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma.. <i>Blood</i> , 2007, 110, 1351-1351.	1.4	6
34	Rituximab/Bendamustine and Rituximab/Cytarabine (RB/RC) Induction Chemotherapy for Transplant-Eligible Patients with Mantle Cell Lymphoma: A Pooled Analysis of Two Phase 2 Clinical Trials and Off-Trial Experience. <i>Blood</i> , 2018, 132, 145-145.	1.4	5
35	Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after Programmed Cell Death 1 (PD-1) / Programmed Cell Death Ligand 1 (PD-L1) Blockade for Classical Hodgkin Lymphoma: Analysis of a Large International Cohort. <i>Blood</i> , 2019, 134, 775-775.	1.4	5
36	A Phase 1, Open-Label, Multi-Center, Multiple-Dose, Dose-Escalation Study of MDX-1342 in Patients with CD19-Positive Refractory/Relapsed Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2009, 114, 3425-3425.	1.4	5

#	ARTICLE	IF	CITATIONS
37	A Phase II Study of Ofatumumab in Combination with ICE or DHAP Chemotherapy in Relapsed or Refractory Aggressive B-Cell Lymphoma Prior to Autologous Stem Cell Transplantation (ASCT). <i>Blood</i> , 2011, 118, 957-957.	1.4	5
38	DC/Aml Fusion Cell Vaccination Administered to AML Patients Who Achieve a Complete Remission Potently Expands Leukemia Reactive T Cells and Is Associated with Durable Remissions. <i>Blood</i> , 2015, 126, 2549-2549.	1.4	5
39	A 78-Year-Old Man with Acute Myeloid Leukemia (AML) and Acute Renal Failure. <i>American Journal of Case Reports</i> , 2014, 15, 364-367.	0.8	5
40	Phase I study of the Bcl-2 inhibitor venetoclax with DA-EPOCH-R as initial therapy for aggressive B-cell lymphomas.. <i>Journal of Clinical Oncology</i> , 2020, 38, 8003-8003.	1.6	4
41	Prognostic Value of Circulating Tumor DNA (ctDNA) in Autologous Stem Cell Graft and Post-Transplant Plasma Samples Among Patients with Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2020, 136, 22-23.	1.4	4
42	PD-1 Blockade for Diffuse Large B-Cell Lymphoma after Autologous Stem Cell Transplantation. <i>Blood</i> , 2018, 132, 706-706.	1.4	3
43	Dendritic Cell Myeloma Fusions Stimulate Anti-Tumor Immunity: Results from Pre-Clinical Studies and a Clinical Trial.. <i>Blood</i> , 2004, 104, 751-751.	1.4	3
44	Everolimus in Combination with Rituximab Induces Complete Responses in Heavily Pretreated Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2011, 118, 1635-1635.	1.4	3
45	Clinical Trial Evaluating DC/AML Fusion Cell Vaccination Alone and in Conjunction with PD-1 Blockade in AML Patients Who Achieve a Chemotherapy-Induced Remission. <i>Blood</i> , 2011, 118, 948-948.	1.4	3
46	Blockade of PD-1 in Combination with Dendritic Cell/Myeloma Fusion Cell Vaccination Following Autologous Stem Cell Transplantation. <i>Blood</i> , 2012, 120, 578-578.	1.4	3
47	Phase II Clinical Trial of Abatacept for Steroid-Refractory Chronic Graft Versus Host Disease. <i>Blood</i> , 2021, 138, 264-264.	1.4	3
48	Clinical Trial Evaluating DC/AML Fusion Cell Vaccination in AML Patients Who Achieve a Chemotherapy-Induced Remission. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, S50.	2.0	2
49	PD-1 Blockade with Pembrolizumab for Classical Hodgkin Lymphoma after Autologous Stem Cell Transplantation. <i>Blood</i> , 2018, 132, 1650-1650.	1.4	2
50	Development of Novel Second Generation DC/Tumor Fusion Vaccine in Lymphoma. <i>Blood</i> , 2019, 134, 392-392.	1.4	2
51	Phase I Study of Vaccination with Dendritic Cell Myeloma Fusions.. <i>Blood</i> , 2007, 110, 284-284.	1.4	2
52	High Response Rates and Encouraging Time-to-Event Data with Lenalidomide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Final Results of a Phase I/II Study.. <i>Blood</i> , 2009, 114, 1218-1218.	1.4	2
53	MUC1 Inhibition Overcomes Chemotherapy Resistance in Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 2473-2473.	1.4	2
54	Phase I Clinical Trial Evaluating Abatacept in Patient with Steroid-Refractory Chronic Graft Versus Host Disease. <i>Blood</i> , 2016, 128, 387-387.	1.4	2

#	ARTICLE	IF	CITATIONS
55	Dendritic Cell Tumor Fusion Vaccination in Conjunction with Autologous Transplantation for Multiple Myeloma.. Blood, 2009, 114, 783-783.	1.4	2
56	Accelerating Learning Health Systems Using Alicanto Collaboration Platforms. JCO Global Oncology, 2022, 8, 62-62.	1.8	2
57	Development of HHV-6-Specific Immunity after Cord Blood Transplantation in Adults Depends on Reconstitution of Thymopoiesis and Regeneration of CD4+ T Cells. Blood, 2019, 134, 3275-3275.	1.4	1
58	Targeting Acute Myeloid Leukemia Stem Cells by MUC1-C Subunit Inhibition. Blood, 2010, 116, 848-848.	1.4	1
59	90Y-Ibritumomab Tiuxetan Followed by Rituximab Is a Safe Treatment Option for Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin's Lymphoma. Blood, 2010, 116, 2866-2866.	1.4	1
60	Pure Red Cell Aplasia after ABO-Mismatched Allogeneic Stem Cell Transplantation Treated with Therapeutic Plasma Exchange and Rituximab. Blood, 2015, 126, 5453-5453.	1.4	1
61	MUC1-C Inhibition Leads to Decrease in PD-L1 Levels Via up-Regulation of Micro RNAs. Blood, 2016, 128, 2871-2871.	1.4	1
62	Outcome of Autologous Stem Cell Transplantation Following PD-(L)1 Based Salvage Therapy for Multiply Relapsed Patients with Classic Hodgkin Lymphoma. Blood, 2019, 134, 4571-4571.	1.4	1
63	Phase I Clinical Trial Evaluating Abatacept in Patients with Steroid-Refractory Chronic Graft Versus Host Disease. Biology of Blood and Marrow Transplantation, 2017, 23, S376.	2.0	0
64	Leukemia Derived Dendritic Cells (LDCs) Are Functionally Deficient and Inferior to DC/Leukemia Fusion Cells as a Tumor Vaccine for AML.. Blood, 2005, 106, 2788-2788.	1.4	0
65	90Y Ibritumomab Tiuxetan and Rituximab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin's Lymphoma.. Blood, 2006, 108, 2752-2752.	1.4	0
66	Targeting MUC1 as a Marker for Myeloid Leukemia Stem Cells by DC/AML Fusions.. Blood, 2007, 110, 1794-1794.	1.4	0
67	A Comparative Analysis of Immune Reconstitution Following Reduced Intensity Conditioning with CAMPATH-1H and Total Lymphoid Irradiation/Anti-Thymocyte Globulin Prior to Allogeneic Stem Cell Transplantation.. Blood, 2009, 114, 1148-1148.	1.4	0
68	MUC1 Inhibition Reverses the Poor Immunogenicity of Leukemia Stem Cells Rendering Them Susceptible to Immunotherapy. Blood, 2011, 118, 1883-1883.	1.4	0
69	Addition of Clofarabine to TLI/ATG Conditioning: Impact on Immune Reconstitution and Clinical Outcomes,. Blood, 2011, 118, 4066-4066.	1.4	0
70	Targeting Leukemia Initiating Cells by MUC1-C Subunit Inhibition. Blood, 2012, 120, 3583-3583.	1.4	0
71	Co-Expression Of The MUC1 Oncoprotein and CD34 On Primary Myeloma Bone Marrow Cells Identifies a Population With Myeloma Initiating Potential. Blood, 2013, 122, 127-127.	1.4	0
72	MUC1 As a Potential Therapeutic Target in Cutaneous T-Cell Lymphoma. Blood, 2014, 124, 808-808.	1.4	0

#	ARTICLE	IF	CITATIONS
73	Delayed Platelet Engraftment after Umbilical Cord Blood Transplant: Relationship to Circulating Levels of Thrombopoietin. Blood, 2014, 124, 3862-3862.	1.4	0
74	Acute Myeloid Leukemia Cells Export c-Myc in Extracellular Vesicles Driving a Proliferation of Immune-Suppressive Myeloid-Derived Suppressor Cells. Blood, 2016, 128, 703-703.	1.4	0
75	Prognostic Value of Minimal Residual Disease (MRD) Among Patients with Classical Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplantation. Blood, 2021, 138, 3491-3491.	1.4	0